Skip to main content
main-content
Top

22-06-2018 | ASCO | Main feed | News

ASCO 2018 in brief

Avelumab–lorlatinib shows efficacy for heavily pretreated ALK-positive NSCLC

medwireNews: The JAVELIN Lung 101 study suggests that the PD-L1 inhibitor avelumab plus the third-generation ALK inhibitor lorlatinib may be a feasible combination in non-small-cell lung cancer (NSCLC) patients with heavily pretreated, advanced ALK-positive disease.

For the phase Ib study, 28 patients who had received any number of prior ALK inhibitor regimens were given avelumab 10 mg/kg every 2 weeks plus lorlatinib 100 mg/day, Alice Shaw, from Massachusetts General Hospital Cancer Center in Boston, USA, told delegates at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

One patient achieved a complete response to treatment, 12 a partial response, and six patients stable disease, giving an objective response rate of 46.4% and a disease control rate of 67.9%; median duration of response was 7.4 months although data are not yet mature.

Summing up, Shaw said the combination had a “manageable safety profile” with “no dose-limiting toxicities”, and that “longer follow-up will be important to establish the true durability of these responses and to better assess the potential benefit of combined avelumab and lorlatinib in ALK-positive lung cancer.”

By contrast, a second regimen consisting of avelumab alongside the ALK inhibitor crizotinib 250 mg twice daily was “not well tolerated” by the 12 patients with advanced ALK-negative NSCLC and no previous PD-1 or PD-L1 targeted therapy, she said, with dose-limiting toxicities reported in 41.7%.

With efficacy no greater than expected for avelumab alone, Shaw concluded that “no further development of this combination is planned.”

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

Related topics